FOSTER CITY, Calif. (AP) -- European regulators have approved the use of a Gilead Sciences treatment that is designed to prolong the effects of HIV drugs.
Tybost, or cobicistat, is a component of Gilead's four-in-one HIV drug Stribild. Stribild is approved in both the U.S. and EU. However the Food and Drug Administration has not approved Tybost by itself. In April the agency said it wouldn't approve Tybost and another medicine until Gilead fixes quality control problems at its manufacturing facilities.
Shares of Gilead Sciences Inc. shares rose $1.19 to $62.92 in afternoon trading.
- Health Care Industry
- Gilead Sciences
- Food and Drug Administration